MultiCell Technologies Receives Two International Trademark Protections

MultiCell Technologies, Inc. (BULLETIN BOARD: MCET) , has received International Trademark Registration No. 846 389 for the name "Biofactories". The Company's patented hepatocytes are termed Biofactories because of their ability to naturally express or produce therapeutic proteins. The Company's immortalized non-tumorigenic adult human hepatocytes are also valuable for use in drug discovery screening applications.

MultiCell Technologies has also been granted International Trademark Registration No. 902 524 for "MultiCell Therapeutics", a name which may be used for one or more of the company's developmental therapeutic products.

MultiCell is a pharmaceutical company developing therapeutics based on immune system modulation, toll receptor techniques, stem cells and other patented drug development techniques. MultiCell's therapeutic pipeline includes potential therapeutics for the treatment of chronic fatigue in MS patients, for treatment of relapsing-remitting MS, for juvenile diabetes, viral infections, influenzas and some cancers.

MultiCell Technologies, Inc. has offices and labs in Lincoln, RI and San Diego, CA. For more information about MultiCell Technologies, please visit http://www.multicelltech.com/. To receive future news releases by email, email MCETinvestor@muticelltech.com.

Caution Regarding Forward-Looking Statements

Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe," "will," "expect," "anticipate," "estimate," "intend," "plan," "forecast," "could," and "would." Examples of such forward looking statements include statements regarding the timing, design, scope, and anticipated results of our clinical development programs. MultiCell bases these forward- looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our products as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations. For additional information about risks and uncertainties MultiCell faces, see documents MultiCell files with the SEC, including MultiCell's report on Form 10-KSB for the fiscal year ended November 30, 2006, and all our quarterly and other periodic SEC filings. MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and each assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.

First Call Analyst:
FCMN Contact:

SOURCE: MultiCell Technologies, Inc.